Follow up analysis of phase III study of gefitinib versus erlotinib in patients with advanced lung adenocarcinoma.
Latest Information Update: 07 Mar 2022
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 31 Jan 2021 Status changed to completed.
- 31 Jan 2021 Primary endpoint (Overall survival of patients with activating mutation according to treatment arm) has not been met.
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer.